| human | Q5 |
| P227 | GND ID | 1233709437 |
| P10058 | IRIS UNIBO author ID | 22015 |
| P8189 | National Library of Israel J9U ID | 987007333417105171 |
| P496 | ORCID iD | 0000-0002-8519-4101 |
| P3829 | Publons author ID | 2247578 |
| P1053 | ResearcherID | J-5979-2016 |
| P1153 | Scopus author ID | 7102271842 |
| P214 | VIAF ID | 273542637 |
| P734 | family name | Picci | Q65112142 |
| Picci | Q65112142 | ||
| Picci | Q65112142 | ||
| P735 | given name | Piero | Q3903143 |
| Piero | Q3903143 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q82615886 | 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients |
| Q39493814 | 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma |
| Q40378150 | 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. |
| Q36029709 | A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma |
| Q56378218 | A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy |
| Q77128805 | Adhesion molecules in high-grade soft tissue sarcomas: correlation to clinical outcome |
| Q50085149 | Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment |
| Q56995815 | Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years |
| Q56999114 | Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy |
| Q68816875 | Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study |
| Q38506118 | Advances in emerging drugs for osteosarcoma |
| Q40320732 | Alpha-tocopheryl succinate alters cell cycle distribution sensitising human osteosarcoma cells to methotrexate-induced apoptosis |
| Q40424759 | Alpha-tocopheryl succinate induces cytostasis and apoptosis in osteosarcoma cells: the role of E2F1. |
| Q73841972 | Altered G1 phase regulation in osteosarcoma |
| Q71340632 | Alveolar soft part sarcoma |
| Q35103838 | An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. |
| Q55032911 | Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma. |
| Q40606723 | Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells |
| Q24170413 | Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types |
| Q34124742 | Aneurysmal bone cyst of the mobile spine: report on 41 cases |
| Q40427655 | Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. |
| Q45125767 | Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone |
| Q33407709 | Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis |
| Q38352962 | Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). |
| Q30988491 | Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. |
| Q91364633 | Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution |
| Q56996677 | Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients |
| Q44438546 | C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. |
| Q34483649 | CD99 acts as an oncosuppressor in osteosarcoma |
| Q34629236 | CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. |
| Q24642797 | CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis |
| Q53333990 | CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. |
| Q39156193 | CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. |
| Q38929303 | CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin |
| Q60628298 | CIC-DUX4fusion-positive round-cell sarcomas of soft tissue and bone: a single-institution morphological and molecular analysis of seven cases |
| Q37641721 | Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma |
| Q33520381 | Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression |
| Q70097844 | Case report 301. Diagnosis: dedifferentiated chondrosarcoma of the upper end of the humerus |
| Q69410685 | Case report 437: Solitary (unicameral, simple) bone cyst of the scapula |
| Q68007639 | Case report 489 |
| Q68053937 | Case report 489: Hibernoma of left thigh |
| Q69659523 | Case report 517. Mesenchymal chondrosarcoma of the femur |
| Q68568990 | Case report 629: Osseous hydatidosis |
| Q40093820 | Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. |
| Q82452570 | Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability |
| Q48350837 | Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues |
| Q73527248 | Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues |
| Q33883583 | Chondrosarcoma of the mobile spine: report on 22 cases |
| Q33273555 | Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers |
| Q33272488 | Chordoma of the mobile spine: fifty years of experience |
| Q70202461 | Clear cell chondrosarcoma of bone. A report of 8 cases |
| Q60050243 | Clinical Significance of Tumor Protein D52 Immunostaining in a Large Series of Ewing's Sarcoma Family of Tumors |
| Q73094960 | Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors |
| Q39995579 | Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. |
| Q56979910 | Clinical outcome of central conventional chondrosarcoma |
| Q60050244 | Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors |
| Q37078506 | Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors |
| Q29028729 | Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma |
| Q36674407 | Comparison of the outcome of conventional osteosarcoma at two specialist international orthopaedic oncology centres |
| Q42453605 | Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects |
| Q44561705 | Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias |
| Q57014087 | Correlation between apoptosis and TP53 status in osteosarcoma |
| Q88317604 | Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence |
| Q73774952 | DNA copy number amplifications in sarcomas with homogeneously staining regions and double minutes |
| Q48501750 | Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. |
| Q56974557 | Diagnostic utility of molecular investigation in extraskeletal myxoid chondrosarcoma |
| Q45998686 | Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases. |
| Q33275511 | Difficulty distinguishing benign notochordal cell tumor from chordoma further suggests a link between them |
| Q47773300 | Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival |
| Q39600616 | Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling |
| Q30439048 | Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors |
| Q37778400 | Emerging drugs for high-grade osteosarcoma |
| Q34121295 | Enchondroma vs. chondrosarcoma: a simple, easy-to-use, new magnetic resonance sign |
| Q40004733 | Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. |
| Q84813125 | Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance? |
| Q84879058 | Epithelial marker expression does not rule out a diagnosis of Ewing's sarcoma family of tumours |
| Q40411164 | Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation |
| Q38573422 | Ewing Sarcoma: Current Management and Future Approaches Through Collaboration |
| Q50234728 | Ewing sarcoma in patients over 40 years of age: a prospective analysis of 31 patients treated at a single institution |
| Q40437869 | Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours |
| Q53641041 | Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. |
| Q71523309 | Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome |
| Q40707005 | Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. |
| Q54386341 | Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. |
| Q36291227 | Fibrocartilaginous mesenchymoma of bone: a single-institution experience with molecular investigations and a review of the literature |
| Q54712822 | Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. |
| Q33267438 | From a 16th century monastery to a 21st century orthopaedic hospital |
| Q40278928 | Full-lung tomograms and bone scanning in the initial work-up of patients with osteogenic sarcoma. A review of 126 cases |
| Q40738122 | Fusion events lead to truncation of FOS in epithelioid hemangioma of bone |
| Q44852513 | Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma |
| Q49041245 | Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis. |
| Q34159317 | Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells. |
| Q57001391 | Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone |
| Q54506099 | Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. |
| Q77470708 | Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization |
| Q46904091 | Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients |
| Q28659642 | Genome-wide association study identifies two susceptibility loci for osteosarcoma |
| Q44634672 | Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. |
| Q69629233 | Giant cell reparative granuloma and other giant cell lesions of the bones of the hands and feet |
| Q56999442 | Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution |
| Q40206789 | Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells |
| Q48312974 | HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma |
| Q101214438 | High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series |
| Q43961345 | High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study |
| Q40366561 | High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma? |
| Q69842508 | Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor |
| Q84750681 | Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support |
| Q35212194 | Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. |
| Q47815298 | Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. |
| Q33441802 | Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial |
| Q40572224 | Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. |
| Q39314094 | Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. |
| Q34755599 | Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis. |
| Q43850675 | Imaging of bone tumors for the musculoskeletal oncologic surgeon. |
| Q48729121 | Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection |
| Q38478426 | Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. |
| Q23924183 | Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33 |
| Q28244685 | In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type |
| Q56378392 | Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53 |
| Q52716117 | Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy. |
| Q40298751 | Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. |
| Q35678071 | Integrated approaches to miRNAs target definition: time-series analysis in an osteosarcoma differentiative model. |
| Q70906953 | Intracortical osteosarcoma: rare entity or early manifestation of classical osteosarcoma? |
| Q49399302 | Intraosseous papillary intralymphatic angioendothelioma (PILA): one new case and review of the literature. |
| Q43831224 | Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. |
| Q57012134 | Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience |
| Q56987024 | Late sarcoma development after curettage and bone grafting of benign bone tumors |
| Q56994814 | Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution |
| Q70087491 | Localized Ewing's sarcoma of bone: ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy |
| Q41613919 | Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. |
| Q41437723 | MDM2 and CDK4 expression in periosteal osteosarcoma. |
| Q54718294 | MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study. |
| Q60548455 | Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry |
| Q52172210 | Malignant fibrous histiocytoma: inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22-evidence for a common genetic defect. |
| Q46658880 | Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. |
| Q39902204 | Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. |
| Q71988520 | Metachronous pulmonary metastases resection in patients with Ewing's sarcoma initially treated with adjuvant or neoadjuvant chemotherapy |
| Q28538155 | Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug |
| Q39061212 | Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation |
| Q35558868 | Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis |
| Q34801108 | Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four years |
| Q34325539 | Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. |
| Q56989588 | Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone |
| Q40725641 | Murine model for skeletal metastases of Ewing's sarcoma |
| Q56991788 | NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients |
| Q36851314 | NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion. |
| Q39752874 | NVP-BEZ235 as a new therapeutic option for sarcomas. |
| Q74323138 | Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies |
| Q74510678 | Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study |
| Q56995093 | Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999 |
| Q56995891 | Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases |
| Q74028567 | Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors |
| Q33369033 | Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. |
| Q34638074 | Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. |
| Q56998385 | No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma |
| Q56985814 | Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol |
| Q41421308 | Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). |
| Q41188714 | Oncogene alterations in primary, recurrent, and metastatic human bone tumors |
| Q56340001 | Osteoblastoma-like osteosarcoma: High-grade or low-grade osteosarcoma? |
| Q66812379 | Osteoid osteoma and osteoblastoma of the talus. A report of 40 cases |
| Q34574274 | Osteosarcoma (osteogenic sarcoma). |
| Q51291339 | Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. |
| Q37994125 | Osteosarcoma of the mobile spine. |
| Q45405959 | Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years |
| Q70535157 | Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma |
| Q50660686 | Outcome of advanced, unresectable conventional central chondrosarcoma. |
| Q46431085 | Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma |
| Q39869264 | Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome |
| Q54071954 | P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. |
| Q38593305 | Paediatric chondrosarcomas: a retrospective review of 17 cases |
| Q37845831 | Palliative therapy for osteosarcoma. |
| Q37409351 | Parosteal osteosarcoma dedifferentiating into telangiectatic osteosarcoma: importance of lytic changes and fluid cavities at imaging |
| Q92288198 | Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients |
| Q56996926 | Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999 |
| Q36364836 | Phenotypic and molecular differences between giant-cell tumour of soft tissue and its bone counterpart. |
| Q57003383 | Platelet-derived growth factors enhance proliferation of human stromal stem cells |
| Q48243209 | Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. |
| Q57004423 | Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival |
| Q40606069 | Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines. |
| Q40240048 | Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma |
| Q37323073 | Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma |
| Q43754201 | Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute |
| Q40448095 | Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma. |
| Q43699064 | Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma |
| Q45743507 | Presence and expression of the simian virus-40 genome in human giant cell tumors of bone. |
| Q48912272 | Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness |
| Q36927145 | Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. |
| Q68780653 | Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarter |
| Q72175063 | Primary chemotherapy and delayed surgery for non-metastatic telangiectatic osteosarcoma of the extremities. Results in 28 patients |
| Q72613107 | Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin |
| Q44646937 | Primary high-grade osteosarcoma: comparison between preadolescent and older patients. |
| Q60628603 | Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation |
| Q56970305 | Primary pseudomyogenic haemangioendothelioma of bone: report of two cases |
| Q35061368 | Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? |
| Q40417879 | Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma |
| Q56998541 | Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution |
| Q35560747 | Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone |
| Q74493909 | Prognostic relevance of C-myc gene expression in giant-cell tumor of bone |
| Q28255834 | Prognostic relevance of CCN3 in Ewing sarcoma |
| Q53586132 | Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study. |
| Q50658268 | Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression. |
| Q70566496 | Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy |
| Q40017274 | Prognostic value of CCN3 in osteosarcoma |
| Q53871865 | Prognostic value of P-glycoprotein in high-grade osteosarcoma. |
| Q48005236 | Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone |
| Q37273398 | Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed |
| Q44382222 | Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. |
| Q34226841 | Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis |
| Q57007989 | Radiological features of 24 periosteal chondrosarcomas |
| Q57006881 | Radiological study of 12 high-grade surface osteosarcomas |
| Q34633416 | Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. |
| Q44089549 | Recurring osteoblastoma initially presenting as a typical osteoid osteoma. Report of two cases |
| Q42820019 | Redundancy of autocrine loops in human osteosarcoma cells. |
| Q33382768 | Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma |
| Q40894843 | Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene |
| Q38555375 | Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. |
| Q57001470 | Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years |
| Q33275974 | Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. |
| Q69608716 | Sacral osteoid osteoma and osteoblastoma: a report of 13 cases |
| Q53408662 | Sclerosing epithelioid fibrosarcoma of the thigh: report of two cases with synchronous bone metastases. |
| Q46052387 | Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets. |
| Q56999338 | Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999 |
| Q51773744 | Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. |
| Q42739226 | Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors |
| Q61794155 | Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group |
| Q38386665 | Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group |
| Q42181980 | Significant association between human osteosarcoma and simian virus 40. |
| Q49240661 | Simultaneous paired analysis of numerical chromosomal aberrations and DNA content in osteosarcoma. |
| Q54172679 | Small cell osteosarcoma: clinicopathologic, immunohistochemical, and molecular analysis of 36 cases. |
| Q52545950 | Soft Tissue Tumors Rarely Presenting Primary in Bone; Diagnostic Pitfalls. |
| Q70557918 | Solid variant of aneurysmal bone cyst |
| Q33419286 | Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. |
| Q33582914 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways |
| Q38950669 | Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma |
| Q56974234 | Surgical treatment and results of 62 patients with epithelioid hemangioendothelioma of bone |
| Q56988430 | Survival in high-grade osteosarcoma: improvement over 21 years at a single institution |
| Q36544082 | Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. |
| Q34607877 | Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. |
| Q37660434 | Targeted therapies in bone sarcomas. |
| Q40344079 | Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma |
| Q39446187 | Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. |
| Q53240644 | Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. |
| Q37182436 | Targeting insulin-like growth factor 1 receptor in sarcomas |
| Q38959358 | Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance |
| Q41737244 | Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. |
| Q53119067 | The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. |
| Q38722433 | The Istituto Rizzoli experience with small cell osteosarcoma. |
| Q53937223 | The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. |
| Q35788810 | The expression of ccn3(nov) gene in musculoskeletal tumors |
| Q33881163 | The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation |
| Q37645458 | The incidental skeletal lesion: ignore or explore? |
| Q37560522 | The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas |
| Q56997856 | The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy |
| Q83912923 | The t(X;6) in subungual exostosis results in transcriptional deregulation of the gene for insulin receptor substrate 4 |
| Q70306822 | The treatment of localized Ewing's sarcoma: the experience at the Istituto Ortopedico Rizzoli in 163 cases treated with and without adjuvant chemotherapy |
| Q37705060 | The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future. |
| Q38917815 | Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. |
| Q57000564 | Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy |
| Q56997632 | Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients |
| Q43938006 | Troglitazione affects survival of human osteosarcoma cells |
| Q60315449 | Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy |
| Q49364445 | Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. |
| Q68009596 | Tumours of the patella |
| Q91117921 | Unlocking bone for proteomic analysis and FISH |
| Q44298538 | Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities |
| Q38918771 | miR-196a expression in human and canine osteosarcomas: a comparative study |
| Q39465507 | miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy |
| Q39228419 | miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. |
| Q39470099 | p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. |
| Q35503066 | p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression |
Search more.